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Abstract
The prognostic impact of TERT mutations has been controversial in IDH-wild tumors, particularly in glioblastomas
(GBM). The controversy may be attributable to presence of potential confounding factors such as MGMT
methylation status or patients’ treatment. This study aimed to evaluate the impact of TERT status on patient
outcome in association with various factors in a large series of adult diffuse gliomas. We analyzed a total of 951
adult diffuse gliomas from two cohorts (Cohort 1, n = 758; Cohort 2, n = 193) for IDH1/2, 1p/19q, and TERT promoter
status. The combined IDH/TERT classification divided Cohort 1 into four molecular groups with distinct outcomes.
The overall survival (OS) was the shortest in IDH wild-type/TERT mutated groups, which mostly consisted of GBMs
(P < 0.0001). To investigate the association between TERT mutations and MGMT methylation on survival of patients
with GBM, samples from a combined cohort of 453 IDH-wild-type GBM cases treated with radiation and
temozolomide were analyzed. A multivariate Cox regression model revealed that the interaction between TERT and
MGMT was significant for OS (P = 0.0064). Compared with TERT mutant-MGMT unmethylated GBMs, the hazard ratio
(HR) for OS incorporating the interaction was the lowest in the TERT mutant-MGMT methylated GBM (HR, 0.266),
followed by the TERT wild-type-MGMT methylated (HR, 0.317) and the TERT wild-type-MGMT unmethylated GBMs
(HR, 0.542). Thus, patients with TERT mutant-MGMT unmethylated GBM have the poorest prognosis. Our findings
suggest that a combination of IDH, TERT, and MGMT refines the classification of grade II-IV diffuse gliomas.
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Introduction
Extensive genomic analyses have recently revealed that
the biology of brain tumors, therefore patients’ clinical
outcomes, is often determined by combinations of specific
genetic and/or epigenetic alterations. The latest edition of
the World Health Organization (WHO) Classification of
Tumours of the Central Nervous System (revised 4th edi-
tion) incorporated molecular classification as a part of the
integrated diagnosis, adding this to conventional histo-
pathology and WHO grading [19]. This is a highly signifi-
cant step in the diagnostic pathology, considering that the
conventional histopathological diagnosis may suffer from
morphological ambiguity and inter-observer discordance,
most typically exemplified by oligoastrocytoma [33]. For
molecular classification to best help standardize diagnoses,
it is critical to test the efficacy of molecular markers to de-
fine specific entities.
Diffuse astrocytoma (DA) and anaplastic astrocytoma
(AA) are best characterized by the presence of IDH1/
IDH2 mutations (“IDH mutation”), most often (but not
always) accompanied by mutations in TP53 and ATRX
[12, 17, 31]. It has been suggested that the IDH mutation
is a founder mutation that precedes TP53 and ATRX
mutations [31]. The presence of IDH mutation is associ-
ated with significantly longer overall survival in astrocy-
toma patients diagnosed, according to the WHO 2007
Classification [11, 36]. Oligodendroglioma is defined by
the concurrent deletions of entire 1p/19q (“1p/19q code-
letion”), which is invariably accompanied by IDH muta-
tion. The 1p/19q codeletion is caused by an unbalanced
t(1;19)(q10;p10) translocation resulting in total loss of
one copy of 1p and 19q [8]. Mutations of FUBP1
(1p31.1) and/or CIC (19q13.2) are found in 52–66 % of
oligodendrogliomas [4, 12]. The spatial/temporal distri-
bution of FUBP1/CIC mutations may be heterogeneous,
whereas the 1p/19q codeletion is homogeneously found
within the tumor tissue [31], and a considerable number
of 1p/19q codeleted tumors have no mutations to
FUBP1/CIC [31]. Thus, astrocytomas and oligodendro-
gliomas will be diagnosed based on molecular
characterization of the IDH and 1p/19q statuses; diffuse
astrocytomas are defined by the presence of IDH1/IDH2
mutations without 1p/19q codeletion, whereas the diag-
nosis of oligodendrogliomas requires the presence of
both IDH mutation and 1p/19q codeletion. Molecular
classification of IDH-wildtype gliomas is somewhat elu-
sive. The great majority of primary GBMs are IDH wild-
type. It has been suggested that most astrocytomas with
wild-type IDH may resolve into other tumor entities,
mostly glioblastomas (GBMs) [28]. For better definition
of GBMs in IDH-wild-type tumors, further classification
of molecular markers is needed.
TERT promoter mutations are very common in GBMs
and oligodendroglial tumors [1, 14]. Mutations occur at
either of the two hotspots (conventionally referred to as
C228T and C250T for their chromosomal coordinates in
the hg19 assembly) in a mutually exclusive manner. The
mutations create de novo GA Binding Protein Transcrip-
tion Factor Alpha Subunit (GABPA) binding sites [3],
causing an increase in TERT mRNA transcription in
GBM [1, 3], a mechanism that would lead to telomerase
upregulation and telomere elongation. The TERT pro-
moter mutations almost always coincide with IDH muta-
tions and 1p/19q codeletion in oligodendrogliomas,
whereas a combination of TERT mutation and wild-type
IDH is the most common genotype observed in GBM.
These findings suggest that the combination of IDH and
TERT mutations may be useful to define glioma sub-
classes. The prognostic impact of TERT mutation in
diffuse gliomas appears to be bivalent, unlike IDH muta-
tion or 1p/19q codeletion. Concurrent mutations of
TERT and IDH predict good prognosis, as an alternative
hallmark of oligodendroglioma, whereas TERT promoter
mutation with wild-type IDH tends to be associated with
poor prognosis, although its use in predicting outcomes
in GBM is controversial [1, 6, 13, 15, 26, 30]. One of the
potential confounding factors in the prognostication of
GBM is the methylation status of the MGMT promoter.
MGMT promoter methylation (“MGMT methylation”) is
a well-established prognostic marker for primary GBM
and a predictive marker for the response to temozolo-
mide in elderly GBM [9, 22, 34].
In this study, we examined the utility of molecular
classification based on the IDH and TERT statuses to
predict clinical courses of patients in association with
various clinical factors, histological diagnosis, and grad-
ing in a large series of newly diagnosed WHO grade II-
IV adult gliomas. We specifically focused on the poten-
tial interaction between MGMT promoter methylation
and TERT mutational statuses to further refine the clin-
ical value of molecular diagnosis. We found that TERT
mutation identifies a subset of GBM patients who are
most resistant to the conventional radiochemotherapy
when MGMT is unmethylated.
Materials and methods
Patient selection
Two cohorts were collected in this study. Cohort 1
was formed to evaluate the prognostic impact of mo-
lecular classification based on IDH and TERT statuses
in adult diffuse gliomas. The inclusion criteria for the
Cohort 1 were as follows: 18 years of age or older,
histological diagnosis of grade II-IV diffuse glioma
originating in the cranium, genomic DNA available
for molecular analysis (extracted from frozen tumor
tissues taken at the time of the initial surgery), and
clinical data available for survival analysis. Out of 881
cases initially collected from 13 institutions in Japan,
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758 cases met the criteria and enrolled in the study
as Cohort 1 (the diagram of case selection is shown
in Fig. 1). To further analyze the impact of TERT
promoter mutation and MGMT methylation status on
survival, Cohort 2 was collected as an independent
set of locally diagnosed GBM. The inclusion criteria
for the Cohort 2 were: 18 years of age or older, histo-
logical diagnosis of GBM, treatment with local irradi-
ation of 50 – 65 Gy and concurrent chemotherapy
with temozolomide after initial surgery, absence of
clinically apparent preceding lower grade gliomas, no
IDH1/2 mutations, clinical data available for survival
analysis, and genomic DNA available for molecular
analysis (extracted from frozen tissues taken at the
time of the initial surgery). Out of 218 cases collected
from four institutions in Japan, 193 cases met the cri-
teria described above and were enrolled in Cohort 2.
Clinical data collected from each institution included
the detailed information as follows: age, sex, pre-
operative Karnofsky Performance status (KPS), extent
of resection, radiation dose, and chemotherapeutic
regimen in initial treatment. The study was approved
by the Institutional Review Board (IRB) at National
Cancer Center (No. 2013–042) and the corresponding
local IRB of the participating centers.
Central pathology review
All cases of Cohort 1 were subjected to central path-
ology review by three senior neuropathologists (T.K.,
M.S., and H.S.). Histological diagnosis was made as a
consensus of the 3 pathologists based on the fourth edi-
tion of WHO Classification (WHO 2007) [18]. Although
the cases of the Cohort 2 were not subjected to these re-
view procedures, the local diagnoses were based on the
WHO 2007 criteria, similar to Cohort 1.
Molecular analysis
Tumor DNA was extracted from frozen tumor tissues
for all cases using a DNeasy Blood & Tissue Kit (Qiagen,
Tokyo, Japan). The details of genetic analysis, including
PCR and sequencing for each gene status, are described
in the Additional file 1: Supplementary materials. The
presence of hotspot mutations in IDH1 (R132) and
IDH2 (R172) was assessed by pyrosequencing for all
cases included in this study, as previously reported [2].
The two mutation hotspots in the TERT promoter were
analyzed in all tumors by Sanger sequencing and/or py-
rosequencing, as previously reported [1]. The mutation
hotspots at codons 27 and 34 of H3F3A and at codon
600 of BRAF were analyzed by Sanger sequencing and/
or pyrosequencing. The copy number statuses of 1p and
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Fig. 1 Flowchart of patient selection. For Cohort 1, 758 out of 881 Grade II-IV cases collected met the eligibility criteria and were analyzed for the
prognostic impact of IDH and TERT status in adult diffuse gliomas. From Cohort 1, 260 GBM patients concurrently treated with TMZ and RT were
further selected (Cohort 1 GBM). For Cohort 2, 193 IDH wild-type GBM cases treated with TMZ plus RT were selected (Cohort 2 GBM). Cohort 1
GBM and Cohort 2 GBM were analyzed for the influences of TERT and MGMT status on survival. GBM, glioblastoma; NF, neurofibromatosis; RT, radi-
ation therapy; TMZ, temozolomide
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19q were determined by multiplex ligation-dependent
probe amplification (MLPA), Microarray-based com-
parative genomic hybridization (aCGH) or microsatellite
analysis [1, 24, 32]. The copy number status of CDKN2A
was also assessed using MLPA or aCGH [1]. The methy-
lation status of the MGMT promoter was analyzed by
pyrosequencing after bisulfite modification of genomic
DNA extracted from tumor specimens as described [25],
with some modifications in the thermal cycling condi-
tions. Based on an outcome-based study to determine an
optimal cutoff to judge MGMT promoter methylation in
a series of 276 newly diagnosed GBMs, we used a cut-off
of ≥ 16 % for MGMT methylation. The details of this
study will be described elsewhere (Ichimura, manuscript
in preparation).
Statistical analysis
Statistical analysis was performed using an SAS package
and JMP version 10 (SAS Institute, Cary, NC, USA).
Categorized data were compared between subgroups
using the chi-square test. The comparison for age distri-
bution was examined with the Student’s t test. The sur-
vival data were analyzed with the log-rank test and
univariate and multivariate Cox regression analyses.
Stepwise procedure was used in multivariate Cox regres-
sion. In multivariate Cox proportional hazard models for
GBM cases including TERT and MGMT, a term of inter-
action between them was also incorporated. A P-value <
0.05 was considered significant in statistical analyses.
Results
Molecular classification based on IDH and TERT defines
distinct subgroups of adult gliomas in Cohort 1
All 758 tumor samples from Cohort 1 were screened for
mutations in IDH1/2 and TERT hotspots and the copy
number status of 1p/19q. The data were determined for
all cases but one, in which the 1p/19q status was not de-
termined. The frequencies of each molecular status for
each histology are shown in Table 1. The molecular sta-
tus, patient background, and clinical information for
each case are provided in Additional file 2: Table S1.
IDH1/2 mutations were present in 38 % of tumors,
mostly a c.395G > A transition in IDH1 (R132H; 274/
286, 96 %). TERT promoter mutations were observed in
51 % (390/758) of tumors. IDH1/2 mutations were com-
mon in grade II-III gliomas (38–96 %), whereas TERT
promoter mutations were frequently observed in oligo-
dendrogliomas (74–83 %) and GBMs (58 %).
The combined IDH/TERT classification divided the
Cohort 1 into four molecular groups, each showing dis-
tinct patient characteristics, histology, or clinical out-
come. The patient backgrounds and molecular status of
Table 1 Mutation types of IDH and TERT in each histological type in Cohort 1 and 2, each
Cohort 1 Cohort 2
Histology DA AA GBM OA AOA OL AO All GBMa
Total 63 106 337 67 103 47 35 758 193
IDH1/2 n(%) R132H 36 (57) 38 (36) 16 (5) 56 (84) 59 (57) 42 (89) 27 (77) 274 (36) 0 (0)
Other mutation 2 (3) 2 (2) 0 (0) 2 (3) 2 (2) 3 (6) 1 (3) 12 (2) 0 (0)
All mutation 38 (60) 40 (38) 16 (5) 58 (87) 61 (59) 45 (96) 28 (80) 286 (38) 0 (0)
TERT n(%) C228T 12 (19) 29 27) 136 (40) 27 (40) 30 (29) 27 (57) 17 (49) 278 (37) 94 (49)
C250T 5 (8) 6 (6) 58 (17) 6 (9) 15 (15) 12 (26) 9 (26) 111 15) 21 (11)
C228T&C250T 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0)
All mutation 18 (29) 35 (33) 194 (58) 33 (49) 45 (44) 39 (83) 26 (74) 390 (51) 115 (60)





























H3.3/H3.1 n(%) K27M 2/34 (6) 6/71 (9) 12/316 (4) 0/20 (0) 1/47 (2) 0/12 (0) 0/10 (0) 21/510 (4) 0/193 (0)
Other mutation 0/34 (0) 0/71 (0) 0/316 (0) 0/20 (0) 1/47 (2) 1/12 (8) 0/10 (0) 2/510 (0.4) 0/193 (0)
BRAF (V600)
n(%)
V600E 1/34 (3) 3/70 (4) 8/313 (3) 0/20 (0) 0/47 (0) 0/12 (0) 0/10 (0) 12/506 (2) 4/193 (2)





2/48 (4) 15/74 (20) 40/229 (17) 1/42 (2) 9/64 (14) 2/28 (7) 3/20 (15) 72/505 (14) N/A
aIDH1/2 mutated cases were excluded for Cohort 2 (see Materials and methods in the manuscript)
AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligoastrocytoma, DA diffuse astrocytoma, Del Deletion, GBM glioblastoma, N/A not
available, OA oligoastrocytoma, OL oligodendroglioma
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each group are summarized in Table 2 and Fig. 2. The
group with mutations in both IDH and TERT (Group A)
mainly consisted of oligodendrogliomas or oligoastrocy-
tomas (82 %). The group with mutation in IDH but not
TERT (Group B) mostly consisted of astrocytomas and
grade II-III oligoastrocytomas. The group with no de-
tectable IDH or TERT hotspot mutations (Group C)
included all types of histology, GBM being the most
Table 2 Patient background and molecular status of Cohort 1
All Group Aa Group Ba Group Ca Group Da p-valueb
Total 758 155 131 237 235
Mean Age at diagnosis(year) 53.7 44.7 41.7 56.7 63.4 <0.0001
Sex M/F 426/332 90/65 75/56 134/103 127/108 0.87
Surgery n (%)
Biopsy only 121 (16) 16 (10) 19 (15) 49 (21) 37 (16) 0.05
KPS n (%)
100 160 (21) 66 (43) 51 (40) 26 (11) 17 (7) <0.0001
90 268 (35) 63 (41) 58 (45) 83 (35) 64 (27)
80 126 (17) 13 (8) 7 (5) 43 (18) 63 (27)
70 94 (12) 6 (4) 8 (6) 38 (16) 42 (18)
− 60 107 (14) 7 (5) 4 (3) 47 (20) 49 (21)
Adjuvant therapy n (%)
CRT 559/748 (75) 83/150 (55) 70/131 (53) 201/235 (86) 205/232 (88) <0.0001
Chemo only 58/748 (8) 32/150 (21) 5/131 (4) 7/235 (3) 14/232 (6)
RT only 43/748 (6) 4/150 (3) 16/131 (12) 13/235 (6) 10/232 (4)
None 88/748 (12) 31/150 (21) 40/131 (31) 14/235 (6) 3/232 (1)
Location n(%)
Cerebrum (with frontal involvement) 370/756 (49) 119/154 (77) 82/131 (63) 86/237 (36) 83/234 (35) <0.0001
Cerebrum (other) 348/756 (47) 34/154 (23) 48/131 (37) 122/237(53) 144/234 (63)
Thalamus 25/756 (3) 1/154 (0.7) 0/131 (0) 18/237 (8) 6/234 (3)
Infratentorium 13/756 (2) 0/154 (0) 1/131 (0.8) 11/237 (5) 1/234 (0.4)
Histology n (%)
DA 63 (8) 12 (8) 26 (20) 19 (8) 6 (3) <0.0001
AA 106 (14) 7 (5) 33 (25) 38 (16) 28 (12)
GBM 337 (44) 9 (6) 7 (5) 136 (57) 185 (79)
OA 67 (9) 30 (19) 28 (21) 6 (3) 3 (1)
AOA 103 (14) 32 (21) 29 (22) 29 (12) 13 (6)
OL 47 (6) 39 (25) 6 (5) 2 (1) 0 (0)
AO 35 (5) 26 (17) 2 (2) 7 (3) 0 (0)
Molecular background n(%)
Total 1p/19q loss 148/757 (20) 144/155 (93) 4/131 (3) 0/237 (0) 0/234 (0) <0.0001
MGMT methylation 386/755 (51) 143/155 (92) 88/129 (68) 72/236 (31) 83/235 (35) <0.0001
H3.3/H3.1 mutation 23/510 (5) 1/31 (3) 0/21 (0) 21/233 (9) 1/235 (0.4) 0.0001
BRAF V600E 12/506 (2) 0/31 (0) 0/21 (0) 9/233 (4) 3/221 (1) 0.21
CDKN2A
Homozygous Del 116/505 (23) 4/89 (4) 7/86 (8) 37/163 (23) 68/167 (41) <0.0001
Heterozygous Del 72/505 (14) 5/89 (6) 6/86 (7) 22/163 (13) 39/167 (23)
AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligoastrocytoma, Chemo Chemotherapy, CRT chemoradiotherapy, DA diffuse
astrocytoma, Del Deletion, F Female, GBM glioblastoma, KPS Karnofsky Performance Status, M Male, N/A not available, OA oligoastrocytoma, OL oligodendroglioma,
RT radiation therapy
aGroup A IDH mutated-TERT mutated, Group B IDH mutated-TERT wid-type, Group C IDH wild-type-TERT wild-type, Group D IDH mutated-TERT mutated
bOne-way ANOVA was applied for age, and Pearson’s chi-square test was done for others in statistical analysis
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common (57 %). Tumors exhibiting TERT mutation with
wild-type IDH (Group D) were mostly GBMs (79 %) or
AAs (12 %).
There was a significant difference in overall survival
(OS) and progression-free survival (PFS) between each
group (p < 0.0001, Log-rank test; Fig. 3). Group A
showed the most favorable prognosis (median OS, not
reached; median PFS, 113.4 months), followed by group
B (median OS, not reached; median PFS, 66.5 months).
Group D showed significantly shorter OS or PFS than
any other group. Multivariate analysis using Cox regres-
sion models including clinicopathological information
also revealed the significant prognostic impact of mo-
lecular classification, histological diagnosis, age, sex, and
surgery (Table 3).
The molecular groups were also associated with pa-
tient age, spatial distribution, and other specific gen-
etic profiles. The IDH-mutated groups (Groups A and
B) comprised younger patients than the IDH wild-
type groups (Groups C and D; 43.3 vs. 60.0 years, re-
spectively; p < 0.0001, Student’s t-test). Among the
IDH-wild-type groups, Group C patients were youn-
ger than those in Group D (56.7 vs. 63.4 years, re-
spectively; p < 0.0001, Student’s t-test). Tumors in the
IDH-mutant groups commonly involved the frontal
lobe. Thalamic or infratentorial tumors were the most
common in Group C (72 and 85 %, respectively). The
great majority of the Group A tumors showed 1p19q
codeletion (93 %). Among the IDH-wild-type tumors,
mutations in H3F3A or HIST1H3B (“histone H3 mu-
tations”) were mostly observed in Group C. Deletion
of CDKN2A was predominantly observed in IDH-
wild-type groups (Groups C and D). The frequency of
TERT mutation-type (C250T or C228T) did not differ
between Group A and Group D (p = 0.11, chi-square
test).
Multivariate Cox regression models revealed differences in
prognostic impact of WHO grade among molecular groups
We performed Cox regression analysis in each group to
investigate whether the molecular groups are prognostic
markers independent of the histological diagnosis. In
Group A, only the patients’ clinical backgrounds (age,
KPS, and surgical history) were associated with overall
survival after multivariate analysis, suggesting that this
group was homogeneous regardless of the WHO grade
(Additional file 2: Table S3). The 1p19q status was not
significantly associated with survival by univariate Cox
regression analysis, although the number of 1p19q intact
tumors (n = 11/155) was too small for statistically con-
clusive results (Additional file 2: Table S3; Additional
file 3: Figure S2). On the other hand, the WHO grade (II
or III) was associated with OS and PFS in both univariate
and multivariate analysis for Group B (Additional file 2:
Table S4). In Group C, the WHO grade was significantly
associated with OS and PFS in univariate analysis, whereas
it was not prognostic in multivariate analysis (Additional
file 2: Table S5). The WHO grade did not have significant
impact on OS in both univariate and multivariate analysis
for Group D (Additional file 2: Table S6). Collectively, the
impact of WHO grade differed according to the molecular
groups.
Interaction between TERT and MGMT in IDH-wild-type GBM
To investigate the impact of the TERT mutations and
MGMT methylation in IDH-wild-type GBMs, we se-
lected IDH-wild-type GBM cases from Cohort 1 who re-





















Fig. 2 A diagram of molecular classification of Cohort 1. All 758 tumors in Cohort 1 are sorted according to their molecular classification based
on their IDH and TERT statuses. The mutation statuses of IDH, TERT, H3F3A, the copy number statuses of 1p/19q and CDKN2A/B BRAF, and MGMT
methylation are shown. Centrally reviewed histology is indicated at the bottom. Gray or colored cells indicate absence or presence of alterations,
respectively. Blank cells denote no data. Group A, IDH mutated-TERT mutated; Group B, IDH mutated-TERT wild-type; Group C, IDH wild-type-TERT
wild-type; Group D, IDH mutated-TERT mutated. AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma;
DA, diffuse astrocytoma; Del, Deletion; GBM, glioblastoma; OA, oligoastrocytoma; OL, oligodendroglioma
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with a dose of 50 – 65 Gy, and whose clinical informa-
tion and MGMT status were available. In total, 260
GBM cases met these criteria (“Cohort 1 GBM”) and
were further analyzed (Fig. 1).
In univariate analysis of Cohort 1 GBM, the TERT mu-
tation status was not associated with either OS or PFS,
whereas the MGMT methylation status was strongly as-
sociated with longer survival (Additional file 2: Table
S7a). However, multivariate analysis revealed that TERT
mutation was associated with OS and PFS. The discord-
ance in these results suggested that the prognostic
impact of TERT mutation may be affected by other fac-
tors. We next performed a multivariate Cox regression
analysis incorporating TERT and MGMT interaction.
This analysis revealed a significant interaction between
TERT and MGMT for both OS and PFS (P = 0.0002 and
0.0342, respectively; Additional file 2: Table S7b). When
compared with the TERT mutated-MGMT unmethylated
group, the hazard ratio (HR) for OS incorporating the
interaction was the lowest in the TERT mutated/MGMT
methylated group (HR, 0.186), then the TERT wild-type/
MGMT methylated group (HR, 0.392), finally the TERT
wild-type/MGMT unmethylated group (HR, 0.476).
To validate the findings in a larger series, we collected
an independent cohort of 193 GBM cases as Cohort 2
(Fig. 1). This cohort was selected using the same criteria
as the Cohort 1 GBMs (see above and Fig. 1), except that
local histological diagnosis was employed. The frequency
of TERT promoter mutations in Cohort 2 (60 %) was
comparable to the GBMs from Cohort 1. The Cohort 1
and Cohort 2 GBMs were then combined and analyzed
(Table 4). When stratified by TERT and MGMT statuses,
their association with OS and PFS were as follows: 1) In
the patients with MGMT methylated tumors, TERT sta-
tus was not associated with either OS or PFS (P > 0.05,
Log-rank test) 2) In the patients with MGMT unmethy-
lated tumors, those with TERT mutant tumors showed
shorter OS and PFS than those with TERT wild-type tu-
mors (P < 0.05, Log-rank test); 3) lack of MGMT pro-
moter methylation was associated with shorter OS and
PFS in both TERT wild-type (Group C GBM) and TERT
mutant (Group D GBM) groups (P < 0.05, Log-rank test;
Fig. 4). As a result, patients with the TERT mutated-
MGMT unmethylated GBMs had the shortest survival
(median OS, 14.6 months), whereas those with TERT
mutated-MGMT methylated GBMs survived the longest
(median OS, 30.0 months).
A multivariate Cox regression model incorporating
age, gender, cohort, KPS, tumor location, surgical his-
tory, TERT, and MGMT revealed that the interaction be-
tween TERT and MGMT was significant for OS in the
combined GBM cohort of 453 cases. Against a reference
of the TERT mutant-MGMT unmethylated GBMs, the
HR for OS incorporating the interaction was the lowest
in the TERT mutant-MGMT methylated GBM (HR,
0.266), followed by the TERT wild-type-MGMT methyl-
ated (HR, 0.317), and the TERT wild-type-MGMT
unmethylated GBMs (HR, 0.542). For PFS, TERT and
MGMT independently influenced survival (Table 5).
When Cohort 2 was analyzed separately, univariate
and multivariate Cox regression analysis for OS and PFS
showed that the TERT and MGMT statuses were inde-
pendent prognostic factors. Interaction between TERT
and MGMT was not statistically significant in this co-










































Fig. 3 Kaplan-Meier analysis of progression free survival (PFS) and overall
survival (OS) of molecular groups in Cohort 1. a. PFS of each molecular
group (n= 734). Median PFS was 113.4 months for Group A, 66.5 months
for Group B, 11.7 months for Group C, and 8.2 months for Group D
(P< 0.0001, Log-rank test). Notably, Group D showed significantly shorter
PFS than other groups (P< 0.0001, Log-rank test). b. OS of each molecu-
lar group (n= 758). Median OS was not reached for Groups A and B,
25.3 months for Group C, and 16.3 months for Group D (P< 0.0001, Log-
rank test). Group D showed significantly shorter survival than any other
groups (P< 0.0001, Log-rank test). Group A, IDH mutated- TERT mutated;
Group B, IDH mutated-TERT wild-type; Group C, IDH wild-type-TERT wild-
type; Group D, IDH mutated-TERT mutated
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Table 3 Univariate and Multivariate Cox regression analysis for all cases of Cohort 1 (n = 758)
Univariate Multivariate
OS PFS OS PFS
HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value
Histology Astro grade II 0.91 0.518–1.594 0.74 1.23 0.788–1.906 0.37 0.58 0.323–1.027 0.06 0.92 0.585–1.461 0.74
Astro grade III 2.14 1.410–3.245 0.0003 1.85 1.291–2.638 0.0008 1.02 0.658–1.566 0.95 0.99 0.682–1.447 0.97
GBM 4.02 2.860–5.635 <0.0001 3.73 2.801–4.974 <0.0001 1.24 0.842–1.813 0.28 1.43 1.024–1.989 0.04
Oligo grade II 0.25 0.127–0.504 <0.0001 0.48 0.313–0.749 0.001 0.42 0.207–0.846 0.02 0.6 0.381–0.928 0.02
Oligo grade III Ref Ref Ref Ref
Molecular group* Group A 0.04 0.023–0.073 <0.0001 0.1 0.070–0.142 <0.0001 0.09 0.048–0.180 <0.0001 0.19 0.124–0.296 <0.0001
Group B 0.12 0.079–0.184 <0.0001 0.18 0.126–0.242 <0.0001 0.29 0.172–0.480 <0.0001 0.33 0.218–0.492 <0.0001
Group C 0.58 0.454–0.735 <0.0001 0.62 0.499–0.773 <0.0001 0.71 0.545–0.919 0.01 0.7 0.553–0.888 0.003
Group D Ref Ref Ref Ref
Location Cerebrum 0.79 0.482–1.305 0.36 0.65 0.430–0.985 0.04 excluded by the factor selection with
step-wise method
0.67 0.427–1.045 0.08
Cerebrum with frontal Involvement 0.40 0.242–0.670 0.0005 0.31 0.203–0.475 <0.0001 0.5 0.316–0.779 0.002
Other Ref Ref Ref
Age 1.048a 1.040–1.057 <0.0001 1.033a 1.027–1.040 <0.0001 1.02a 1.011–1.029 <0.0001 1.01a 1.003–1.018 0.007
Sex M Ref Ref Ref Ref
F 0.91 0.724–1.134 0.39 0.95 0.781–1.150 0.58 0.72 0.572–0.905 0.005 0.81 0.663–0.982 0.03
KPS 0.971b 0.965–0.976 <0.0001 0.98b 0.974–0.985 <0.0001 0.99b 0.983–0.997 0.008 excluded by factor selection with
step-wise method
Surgery Biopsy 1.85 1.416–2.427 <0.0001 1.41 1.092–1.817 0.008 2.05 1.522–2.755 <0.0001 1.6 1.204–2.121 0.001
Removal Ref Ref Ref Ref
Adjuvant Therapy CRT 2.02 1.132–3.601 0.02 1.78 1.110–2.868 0.02 excluded by factor selection with step-
wise method
excluded by factor selection with
step-wise method
Chemo 0.84 0.392–1.792 0.65 0.87 0.472–1.587 0.64
RT Ref Ref
None 0.45 0.197–1.010 0.05 0.74 0.411–1.333 0.32
Astro grade II diffuse astrocytoma, Astro grade III anaplastic astrocytoma, Chemo Chemotherapy, C.I. Coefficient interval, CRT chemoradiotherapy, F Female, GBM glioblastoma, HR hazard ratio, KPS Karnofsky
Performance status, M Male, mut mutatant, Oligo grade II oligodendroglioma and oligoastrocytoma, Oligo grade III anaplastic oligodendroglioma and anaplastic oligoastrocytoma, OS overall survival, PFS progression
free survival, Ref Reference, RT radiation therapy, wt wild type
*Group A IDH mutated-TERT mutated, Group B IDH mutated-TERT wid-type, Group C IDH wild-type-TERT wild-type, Group D IDH mutated-TERT mutated

















In this study, we investigated the efficacy of TERT pro-
moter mutation as a diagnostic and/or prognostic
marker in combination with IDH mutation and MGMT
methylation in a large series of newly diagnosed adult
gliomas with detailed clinical information and a rela-
tively homogeneous background, including postoperative
treatment, in particular for GBM. Our results indicated
that molecular classification based on the IDH and
TERT statuses defines four groups within adult diffuse
gliomas of grade II-IV, each showing distinct clinical-
pathological features such as histological type, age, or
tumor location. TERT promoter mutation was a favor-
able prognostic factor in IDH mutated tumors, whereas
it was an unfavorable prognostic factor in IDH wild-type
tumors. The most striking finding was that the prognos-
tic impact of TERT promoter mutation may depend not
only on the IDH status but also on the MGMT methyla-
tion status.
The prognostic value of TERT mutation in GBMs has
been controversial. Some have suggested that TERT sta-
tus did not have an impact on OS in IDH wild-type
GBMs after adjusting by age and gender [6, 26], whereas
others found an adverse prognostic impact of TERT mu-
tation by multivariate analysis including treatment [16,
30]. This discrepancy may be due to insufficient cohort
size or uneven treatment in some of the cohorts. Clinical
background may also be a confounding factor. For ex-
ample, TERT mutation is strongly associated with higher
age, which in itself is a well-known prognostic factor
and affects treatment choice. In the present study, the
prognostic impact of TERT was validated in two inde-
pendent cohorts of GBMs with similar clinical back-
grounds in which molecular tests were thoroughly
performed.
A potentially more significant possibility is the pres-
ence of additional confounding factors that influence
survival of GBM patients in association with the TERT
status. MGMT methylation is a well-established favor-
able prognostic marker for survival in GBM patients,
and predicts the response to temozolomide in elderly
GBM patients [9, 22, 34]. We therefore investigated the
potential interaction between TERT mutation and
MGMT methylation status in newly diagnosed GBM pa-
tients who received a standard treatment with concomi-
tant temozolomide and radiation therapy in Cohort 1 as
Table 4 Patient background and molecular status of analysis for GBM cohort
Cohort Alla Cohort 1 Cohort 2 P-valueb
Total 453 260 193
Mean Age at diagnosis 61.0 59.3 63.3 0.0007
Sex M/F 249/204 152/108 97/96 0.0827
Locationc
Cereberal with frontal involvement 152 (34) 87 (33) 65 (34) 0.985
Cerebral (other) 277 (61) 160 (62) 117 (61)
Other 22 (5) 13 (5) 9 (5)
KPS
100 56 (12) 12 (5) 44 (23) <0.0001
90 132 (29) 81 (31) 51 (26)
80 111 (25) 73 (28) 38 (20)
70 85 (19) 53 (20) 32 (17)
− 60 69 (15) 41 (16) 28 (15)
TERT/MGMT
Mut/Met 88 (19) 48 (18) 40 (21) 0.921
Mut/Un-met 175 (39) 100 (38) 75 (39)
Wt/Met 64 (14) 38 (15) 26 (13)
Wt/Un-met 126 (28) 74 (28) 52 (27)
Surgery
Removal 421 (93) 238 (92) 183 (95)
Biopsy only 32 (7) 22 (8) 10 (5) 0.178
aIDH1/2 mutated cases were excluded for this analysis (see Materials and methods in the manuscript)
bStudent’s t-test was applied for the statistical analysis of age, and Pearson’s chi-square test was done for others
cData of Location was not available in 2 cases of Cohort2
F Female, GBM glioblastoma, KPS Karnofsky Performance Status, M Male, Met MGMT methylated, Mut TERT mutated, N/A not available, Un-met MGMT
unmethylated, wt TERT wild-type
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well as the combined GBM cohort. Our results indicate
that the prognostic impact of TERT mutation is strongly
influenced by the MGMT methylation status. The limita-
tion of this study is that the interaction was validated in
the combined cohort but not in the Cohort 2 alone,
most likely because of the insufficient cohort size. A fur-
ther validation in a larger cohort is warranted.
Our finding that the subset of GBMs defined as having
TERT mutation and unmethylated MGMT have the
poorest prognosis has important clinical implications.
Our results conclusively demonstrated that TERT muta-
tion is one of the most powerful predictors of survival in
GBM patients, along with the MGMT methylation sta-
tus. It has been shown that temozolomide is effective for
GBM with methylated MGMT. Patients with MGMT
unmethylated GBM who receive only minimal benefit
from current standard treatments including temozolo-
mide are the primary population who require new thera-
peutic agents [10]. TERT may thus serve as an
alternative therapeutic target for these patients.
Currently, Imetelstat is the only telomerase inhibitor
that has been tested in clinical trials [23]. Imetelstat is
an oligonucleotide inhibitor to TERC, an RNA subunit
of telomerase, but not a direct inhibitor of TERT. Clin-
ical anti-oncogenic activity of Imetelstat has yet to be
demonstrated. In addition to its activity as the reverse
transcriptase for telomerase, TERT is reported to have
activity as an RNA-dependent RNA polymerase (RdRP)
[20]. RdRP plays an essential role in RNA silencing by
generating double-stranded RNAs, which are processed
into microRNAs [20, 21]. It has been suggested that
TERT is involved in diverse cellular functions, such as
heterochromatin formation or maintenance of tumor-
initiating cells through its RdRP activity. Recently, a spe-
cific inhibitor for RdRP that suppresses growth of
platinum-resistant ovarian cancer cell lines with TERT
mutation and upregulation has been proposed [35]. A
pre-clinical study in GBM is underway (Takahashi, in
preparation).
The biological mechanism for the interaction between
TERT mutation and MGMT methylation that influences
patient survival is currently unclear. A broad spectrum
of the biological consequences of TERT activation, for
example by microRNAs generated through TERT-RdRP,
may affect the response to chemotherapy and/or
radiotherapy.
One of the major challenges of the integrated diagno-
sis system for adult gliomas is whether histological diag-
nosis or WHO grading still have survival impact after
stratification by molecular information. In our study, a
multivariate analysis revealed that the histological diag-
nosis continues to be a significant predictor of survival.
We further investigated the prognostic value of histo-
logical diagnosis in relation to clinical information in
each subgroup.
We found that the WHO grade had no significant im-
pact on OS in either Groups A or D, suggesting that


















































Fig. 4 Kaplan-Meier analysis for survival, stratified by TERT and MGMT
statuses in 453 GBM cases treated with radiation plus temozolomide.
a. PFS of GBM cases (see text for definition). Median PFS was
14.5 months for TERT mutated-MGMT methylated (Mut/Met),
12.8 months for TERT wild-type-MGMT methylated (WT/Met),
9.8 months for TERT wild-type-MGMT unmethylated (WT/Un-met),
and 7.2 months for TERT mutated-MGMT unmethylated (Mut/Un-
met) (P < 0.0001, Log-rank test). The Mut/Un-met group showed
shorter PFS than WT/Un-met (P = 0.0003, Log-rank test), whereas the
differences in PFS between the MGMT methylated groups (between
Mut/Met and WT/Met) was not significant (P = 0.62, Log-rank test).
b. OS of the GBM cases. Median OS was 30.0 months for Mut/Met,
26.5 months for WT/Met, 18.8 months for WT/Un-met, and
14.6 months for Mut/Un-met (P < 0.0001, Log-rank test). The Mut/
Un-met group had shorter OS than WT/Un-met (P < 0.0001, Log-rank
test), whereas the difference in OS between Mut/Met and WT/Met
was not significant (P = 0.83, Log-rank test). GBM, glioblastoma; OS,
overall survival; PFS, progression free survival
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Table 5 Univariate and multivariate Cox regression analysis for GBM cohort (n = 453)
Univariate Multivariate
OS PFS OS PFS
HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value HR 95 % C.I. p-value
Cohort Cohort 1 0.81 0.643–1.030 0.09 1.11 0.884–1.398 0.37 excluded by factor selection with step-
wise method
excluded by factor selection with step-
wise method
Cohort 2 Ref Ref
Location Cerebrum 0.91 0.504–1.624 0.74 0.81 0.489–1.357 0.43 excluded by factor selection with step-
wise method
excluded by factor selection with step-
wise method
Cerebrum with Frontal Involvement 0.93 0.511–1.705 0.82 0.78 0.458–1.317 0.35
Other Ref Ref
Age 1.015a 1.004–1.025 0.006 1.004a 0.995–1.013 0.38 1.01a 1.004–1.025 0.008 excluded by factor selection with step-
wise method
Sex M Ref Ref excluded by factor selection with step-
wise method
excluded by factor selection with step-
wise method
F 0.72 0.570–0.918 0.008 0.78 0.621–0.975 0.03
KPS 0.992b 0.985–0.999 0.03 0.999b 0.992–1.006 0.74 0.99b 0.982–0.997 0.009 excluded by factor selection with step-
wise method
Surgery Biopsy 2.59 1.725–3.899 <0.0001 2.06 1.349–3.130 0.0008 3.15 2.082–4.769 <0.0001 2.22 1.454–3.380 0.0002
Removal Ref Ref Ref Ref
TERT wild-type 0.73 0.568–0.925 0.01 0.73 0.581–0.922 0.008 Interacts with MGMT <0.0001 0.65 0.513–0.821 0.0003
mutated Ref Ref Ref
MGMT Methylated 0.43 0.325–0.561 <0.0001 0.51 0.396–0.656 <0.0001 Interacts with TERT <0.0001 0.48 0.368–0.613 <0.0001
Unmethylated Ref Ref Ref






Chemo Chemotherapy, C.I. Coefficient interval, CRT chemoradiotherapy, F Female, GBM glioblastoma, HR hazard ratio, KPS Karnofsky Performance status, M Male, Met MGMT methylated, Mut TERT mutated, OS overall
survival, PFS progression free survival, Ref Reference, RT radiation therapy, Un-met MGMT unmethylated, Wt TERT wild-type
aHR is for each one year increase
















homogeneous (Additional file 2: Table S10). Virtually all
tumors allocated to Group A are molecularly scored as
oligodendroglial tumors, because the great majority of
them presented total 1p19q codeletion. There remains a
controversy whether or not TERT-IDH co-mutated, but
not 1p19q codeleted, tumors are oligodendrogliomas.
Along with a large-scale analysis reported by Eckel-
Passow et al. [6], those paradoxical cases showed prog-
nosis comparable to the codeleted tumors, suggesting
that those tumors could be regarded as oligodendrogli-
omas. Group D tumors showed universally dismal prog-
nosis regardless of the histological subtype, indicating
that this group is biologically bona fide GBM and that
grade II-III tumors in this group should be regarded as
under-diagnosed GBM.
On the other hand, a univariate analysis identified
WHO grade as a factor significantly associated with sur-
vival in Group B (IDH mutated-TERT wild-type, repre-
senting astrocytomas), and a multivariate analysis for
survival in Group B also identified WHO grade (II or III)
as a prognostic factor in the present study. These results
are in contrast to recent reports that found no survival
impact of WHO grade in IDH mutated astrocytomas [27,
29]; however, it supports the results of another study [6].
So far, there are no molecular markers that define WHO
grades. Our results and others, however, suggest that
WHO grade may still be relevant in some types of gli-
omas. The limitation of these studies is that the treatment
of low-grade astrocytomas may be inconsistent and have
potentially confounded the results. A prospective study
with homogeneously treated patients in clinical trials
would be needed to clarify the significance of WHO grade
in the era of molecular diagnostics.
The Group C remains enigmatic. This triple negative
group has highly heterogeneous backgrounds, including
histological diagnosis, tumor location, and other genetic
traits. This group mainly consists of adult GBMs, how-
ever it also contains pediatric types of GBM that harbor
H3F3A mutations and indolent tumors resembling
pediatric lower grade gliomas with BRAF mutations. A
large scale analysis based on genome-wide methylation
analysis identified tumors exhibiting methylation profiles
similar to pilocytic astrocytomas, as well as tumors re-
sembling pediatric GBMs in the IDH wild-type group
[5]. Although WHO grade II and III tumors in Group C
showed slightly better outcomes compared with the
grade IV counterparts, the prognoses of the grade IV tu-
mors in Group C were comparable with Group D. This
shows that at least histologically proven GBMs in Group
C are clinically relevant GBMs. The question remains
whether the triple negative grade II-III tumors are bio-
logically under-diagnosed GBMs, or if at least some of
them form a separate sub-entity of genuine “Diffuse
(Anaplastic) astrocytoma, IDH wild-type” tumors with
an intermediate prognosis between those with IDH mu-
tations and GBM. Further studies to establish molecular
markers that unequivocally define GBM (e.g., EGFR
amplification, monosomy 10/trisomy 7, or co-gain of
chromosomes 19/20 [7, 28]) on a larger collection of the
triple negative/Group C tumors are warranted.
In this study, using a large cohort of newly diagnosed
adult gliomas with precise clinical information, we dem-
onstrated that molecular classification using IDH and
TERT statuses is a strong prognostic marker of adult gli-
omas. The IDH-TERT classification efficiently identifies
molecularly defined oligodendrogliomas and astrocyto-
mas equivalent to the IDH-1p/19q-based classification.
Although an accurate determination of total 1p/19q
codeletion may require laborious and expensive molecu-
lar tests, examination of two hotspots in the TERT pro-
moter is comparatively simple. Moreover, we found that
a combination of TERT mutation and the MGMT
methylation status classified GBMs into clinically rele-
vant subgroups, identifying TERT mutated-MGMT
unmethylated tumors as having the most severe out-
come, and thus highlighting TERT as a primary target
for novel therapies. Thus, by using TERT mutation as an
additional biomarker, the molecular classification pre-
sented in this study will refine the integrated diagnostic
system and prognostication of glioma patients. Our re-
sults emphasize the importance of combining molecular
markers such as IDH, 1p/19q, TERT, and MGMT for ac-
curate molecular diagnosis, prognostication, and the
choice of treatment in clinical trials, as well as in routine
clinical practice for glioma patients.
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